-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oppenheimer Lowers Avalo Therapeutics (NASDAQ:AVTX) Price Target to $10.00
Oppenheimer Lowers Avalo Therapeutics (NASDAQ:AVTX) Price Target to $10.00
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) had its price objective decreased by investment analysts at Oppenheimer to $10.00 in a research note issued on Tuesday, Stock Target Advisor reports. Oppenheimer's price objective would indicate a potential upside of 72.41% from the company's current price.
Avalo Therapeutics Price Performance
NASDAQ:AVTX traded up $0.03 during trading hours on Tuesday, hitting $5.80. 11,743 shares of the company's stock traded hands, compared to its average volume of 41,421. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.84. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 5.23. The stock's fifty day moving average price is $4.92 and its two-hundred day moving average price is $5.19.
Get Avalo Therapeutics alerts:Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AVTX. Leo Brokerage LLC acquired a new position in Avalo Therapeutics during the first quarter valued at $45,000. Assenagon Asset Management S.A. acquired a new position in Avalo Therapeutics in the 3rd quarter worth about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth about $506,000.
About Avalo Therapeutics
(Get Rating)Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Recommended Stories
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) had its price objective decreased by investment analysts at Oppenheimer to $10.00 in a research note issued on Tuesday, Stock Target Advisor reports. Oppenheimer's price objective would indicate a potential upside of 72.41% from the company's current price.
据Stock Target Advisor报道,在周二发布的一份研究报告中,奥本海默的投资分析师将阿瓦洛治疗公司(纳斯达克:AVTX-GET评级)的目标价下调至10.00美元。奥本海默的目标价格将表明,该公司目前的价格可能上涨72.41%。
Avalo Therapeutics Price Performance
Avalo治疗药物的性价比
NASDAQ:AVTX traded up $0.03 during trading hours on Tuesday, hitting $5.80. 11,743 shares of the company's stock traded hands, compared to its average volume of 41,421. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.84. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 5.23. The stock's fifty day moving average price is $4.92 and its two-hundred day moving average price is $5.19.
纳斯达克:AVTX周二在交易时段上涨0.03美元,触及5.8美元。该公司有11,743股股票易手,而其平均成交量为41,421股。Avalo治疗公司的12个月低点为2.42美元,12个月高位为27.84美元。该公司的速动比率为1.07,流动比率为1.07,债务权益比率为5.23。该股的50日移动均线价格为4.92美元,200日移动均线价格为5.19美元。
Institutional Inflows and Outflows
机构资金流入和流出
Several large investors have recently bought and sold shares of AVTX. Leo Brokerage LLC acquired a new position in Avalo Therapeutics during the first quarter valued at $45,000. Assenagon Asset Management S.A. acquired a new position in Avalo Therapeutics in the 3rd quarter worth about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth about $506,000.
几家大型投资者最近买卖了AVTX的股票。Leo Brokerage LLC在第一季度收购了Avalo治疗公司的一个新头寸,价值4.5万美元。Assenagon Asset Management S.A.在第三季度收购了Avalo Treeutics的一个新头寸,价值约5.2万美元。复兴技术公司在第一季度将其在阿瓦洛治疗公司的地位增加了819.1%。复兴科技有限责任公司在上个季度额外购买了327,241股后,现在拥有367,193股该公司股票,价值266,000美元。高盛公司在第二季度将其在阿瓦洛治疗公司的头寸增加了23.8%。高盛股份有限公司在上个季度增持了124,769股后,目前持有649,653股该公司股票,价值324,000美元。最后,Millennium Management LLC在第二季度获得了Avalo治疗公司的一个新职位,价值约506,000美元。
About Avalo Therapeutics
关于Avalo Treateutics
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家临床阶段的精密药物公司,为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002,这是一种完全人类抗光的单抗,正在进行第二阶段临床试验,用于治疗非嗜酸性哮喘以及炎症性肠道疾病,包括中到重度克罗恩病和溃疡性结肠炎;以及第三阶段临床试验,用于治疗新冠肺炎急性呼吸窘迫综合征。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- 不要追逐沃尔玛更高,等待超低价格
- 家得宝的业绩(和机构)是劳氏的催化剂吗?
- 三只细价股在11月大动干戈
- 安捷伦在下周第四季度报告发布前仍在买入区间
- WayFair仍有其公平份额的问题
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧